


# Arterielle Hypertonie 2024



Marcus Säemann  
6.Med.Abt. mit Nephrologie & Dialyse  
Klinik Ottakring, Wien

- Häufigste non-communicable disease
- betrifft etwa 30 % der westlichen Bevölkerung
- altersabhängiger Anstieg der Prävalenz auf bis zu 60 % bei Menschen  $\geq 65$  Jahren

- ✓ hämorrhagischem oder ischämischem Schlaganfall
- ✓ koronare Herzkrankheit mit Myokardinfarkt
- ✓ ischämischer Kardiomyopathie, Herzinsuffizienz
- ✓ plötzlichem Herztod
- ✓ Vorhofflimmern
- ✓ periphere arterielle Verschlusskrankheit
- ✓ hypertensive Nephropathie
- ✓ hypertensive Retinopathie
- ✓ Demenz

**Erhöhter Blutdruck ist der häufigste vermeidbare kardiovaskuläre Risikofaktor und verantwortlich für bis zu 10 Millionen Todesfälle pro Jahr weltweit**

# HYPERTENSION: ACT NOW!

## How to prevent hypertension?

- Reduce salt (to less than 5g daily)
- Eat fruit and vegetables regularly
- Avoid saturated fats and trans fats
- Avoid tobacco
- Reduce alcohol
- Be physically active, daily



## How to detect hypertension?

Health workers should regularly check people's blood pressure.



**NO SYMPTOMS  
DOES NOT MEAN  
normal blood pressure**

People might have high blood pressure **WITHOUT ANY WARNING SIGNS OR SYMPTOMS.**

Isoleucine Angiotonin Octapeptide, J. Am. Chem. Soc. **79**:5697-5703 (Nov. 5) 1957. Hoobler, S. W.: Interpretive Review of Conference Proceedings, Circulation **17**:825 (April, pt. 2) 1958.

5. Corcoran, A. C.; Dustan, H. P.; Taylor, R. D.; and Page, I. H.: Management of Hypertensive Disease, Am. J. Med. **17**:383-394 (Sept.) 1954.

6. Burn, J. H., and Rand, M. J.: Action of Sympathomimetic Amines in Animals Treated with Reserpine, J. Physiol. **144**:314-336 (Dec. 4) 1958.

7. Maxwell, R. A.; Ross, S. D.; and Plummer, A. J.: Pharmacology of Hexahydro-1-azepinepropionamidoxime Dihydrochloride (Su-4029), J. Pharmacol. & Exper. Therap. **123**:128-139 (June) 1958.



## CLINICAL STUDIES ON HYDROCHLOROTHIAZIDE— ANTIHYPERTENSIVE AND METABOLIC EFFECTS

Victor Vertes, M.D.

and

Mervyn Sopher, M.D., Cleveland

# More history...

- In 1961 Arthur Guyton developed the theory of pressure natriuresis
- In 1967 and 1970 **Veterans Administration Cooperative Studies** demonstrated treatment of HTN (reserpine, chlorothiazide, hydralazine, and guanethidine) reduced stroke and heart failure.
- 1960-1980's:  
The pharmaceutical industry was actively searching for more effective and better tolerated medications.

**Table 2.** Dates of Discovery of Antihypertensive Drugs or Drug Classes (Table

Year(s)	Antihypertensive Agent(s)
1900	Sodium thiocyanate
1931	Reserpine
1947–1950	Ganglion blocking drugs
1958	Thiazide-type diuretics
1950s	Hydralazine
1950s	Guanethidine
1957	Spironolactone
1960	Methyldopa
1973	$\beta$ -Receptor blockers (eg, propranolol)
1970s	Central $\alpha_2$ agonists (eg, clonidine)
1975	Peripheral $\alpha_1$ receptor blockers (eg, prazosin)
1977	ACE inhibitors (eg, captopril)
1977	Calcium channel blockers (eg, verapamil, nifedipine)
1993	Angiotensin II receptor blockers (eg, losartan)
2000	Renin inhibitors (eg, aliskiren)

# Relevant clinical trials



- 1991 **SHEP** study (systolic HTN in the elderly program) showed benefits of treating BP >160 mmHg with chlorthalidone + atenolol
- 1997 **DASH** study showed a diet rich in fruits, vegetables, and low-fat dairy products substantially reduced blood pressure in adults with high normal blood pressures or mild hypertension
- 1998 **UKPDS** showed “tight control” <150/85 mmHg benefited more diabetics than non-diabetics
- 2002 **AASK** showed ACEI offered more renal protection compared to CCB

# 21<sup>st</sup> century clinical trials

- 2002 **ALLHAT** trial showed non inferiority of diuretic vs. ACEI/CCB
- 2008 **ACCOMPLISH** study showed superiority of combination of ACEI + CCB vs. ACEI + thiazide (HCTZ) for CV outcomes
- 2010 **ACCORD** study showed no significant benefit in outcomes with SBP 140 vs. 120 mmHg in diabetics
- 2015 **SPRINT** trial showed significant mortality (27%) and cardiovascular benefits (25%) in group with SB goal 120 mmHg vs. 140 mmHg in **non-diabetic** patients.
- Most trials have failed to show significant differences in cardiovascular outcomes with different drug regimens, if equivalent decreases in blood pressure were achieved.

# Network Meta-analysis of Effects of SBP Reduction on Major CV Events

- 42 **RCTs** including 144,220 patients
- General population






# SPRINT\*: CKD subgroup (N= 2646)

**\*stopped early for ethical reasons:**

**overwhelming CV & survival benefit**




	Number With Data									
	0	6	12	18	24	30	36	42	48	54
Standard:	1316	1215	1156	1117	1087	1022	766	480	230	46
Intensive:	1330	1246	1194	1145	1136	1054	804	515	268	58
	Mean Number of Meds									
Standard:	2.1	2.0	2.0	2.0	2.1	2.0	2.1	2.1	2.1	2.0
Intensive:	2.1	2.9	3.0	3.0	3.0	3.0	2.9	2.9	3.0	3.1


# SPRINT (Target SBP <120 mm Hg vs. <140 mm Hg)

Primary Outcome (Cardiovascular events = MI, ACS, stroke, CHF, CV death)

Entire Cohort




CKD subgroup




No effect modification by baseline CKD

# Outcomes in SPRINT-Seniors (>75 yr) Cohort (N=2,636)




# Effect of Intensive SBP Treatment on Cognition in SPRINT

## Probable Dementia



## Composite of Probable Dementia or Mild Cognitive Impairment



# Adverse Events in CKD Subgroup in SPRINT


	No. (%) of Participants with AE		HR	P
	Intensive BP	Standard BP		
Hypotension	51 (3.8)	38 (2.9)	1.34	0.17
Syncope	54 (4.1)	42 (3.2)	1.28	0.22
Injurious fall	125 (9.4)	138 (10.5)	0.90	0.40
<b>AKI/ARF</b>	<b>114 (8.6)</b>	<b>78 (5.9)</b>	<b>1.46</b>	<b>0.01</b>
K <3.0 mmol/l	30 (2.2)	16 (1.2)	1.87	0.04
K >5.5 mmol/l	106 (8.0)	78 (5.9)	1.36	0.04
<b>TOTAL SAE</b>	<b>627 (47.1)</b>	<b>640 (48.1)</b>	<b>0.98</b>	<b>0.67</b>

# Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control


## A Secondary Analysis of a Randomized Clinical Trial

Byron C. Jaeger, PhD; Adam P. Bress, PharmD, MS; Joshua D. Bundy, PhD; Alfred K. Cheung, MD; William C. Cushman, MD; Paul E. Drawz, MD; Karen C. Johnson, MD, MPH; Cora E. Lewis, MD, MSPH; Suzanne Oparil, MD; Michael V. Rocco, MD; Stephen R. Rapp, PhD; Mark A. Supiano, MD; Paul K. Whelton, MD; Jeff D. Williamson, MD, MHS; Jackson T. Wright Jr, MD, PhD; David M. Reboussin, PhD; Nicholas M. Pajewski, PhD


**A** Cumulative incidence of CVD and non-CVD mortality by treatment group



**B** Time-dependent HR for CVD mortality estimated from a competing risks regression model



## Poor Correlation Between Routine and Standardized Office BP in CKD



- N = 275 CKD
- eGFR  $29 \pm 10$  ml/min/1.73m<sup>2</sup>
- Bland-Altman plot with limits of agreement

← +20.7 mm Hg

← -12.7 mm Hg

← -46.1 mm Hg

Average of standardized and routine SBP (mm Hg)


## Die optimale Messmethode

Umgebungsfaktoren, richtige Position der Patienten, validierte Messgeräte mit patientengerechter Manschette, 3-malige Messung



“It’s great for reducing White Coat Hypertension.”

- ruhiger Raum
- 30 Minuten vorher nicht Rauchen, kein Kaffee, kein Sport
- Harnblase sollte leer sein
- 3–5 Minuten entspannen
- 3 Messungen im Intervall von 1 Minute
- Durchschnitt der letzten 2 Messungen verwenden



## REVIEW

---

# Is the KDIGO Systolic Blood Pressure Target <120 mm Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice?

Indranil Dasgupta<sup>1</sup>, Carmine Zoccali<sup>2</sup>


**ABSTRACT:** Meticulous management of hypertension is important in chronic kidney disease (CKD) to reduce the risk of cardiovascular disease, mortality, and progression of CKD. The recently published Kidney Disease Improving Global Outcomes (KDIGO) guideline on blood pressure (BP) management in CKD stresses the importance of standardized BP measurement and strict control of BP. This is a useful document that will help to improve the management of hypertension in CKD globally. However, the recommendation of systolic BP target of <120 mm Hg by KDIGO is controversial. It is based on weak evidence derived mainly from a single randomized controlled trial and its CKD subgroup analysis. Here, we review the current evidence surrounding BP target in CKD. We argue that the target recommended by KDIGO is not generalizable to the majority of people with CKD. Standardized BP measurements are challenging to implement outside specialist hypertension and research clinics, and the target of <120 mmHg BP systolic cannot be extrapolated to routine clinic BP measurements. If applied to routine BP measurement, this target will expose the multimorbid and frail CKD patients to the risk of adverse events including falls and fractures. Furthermore, it will not be achievable in the majority of CKD patients. The target recommended by KDIGO is an outlier among contemporary major international hypertension guidelines and is likely to perplex clinicians. We believe the KDIGO-recommended target systolic BP <120 mmHg for CKD is inappropriate in the majority of CKD patients and it may even be harmful for patients managed in routine clinical practice.

# SASS

## Trial design

- China
- Multicenter, RCT
- 8511 patients with HTN aged 60-80
- Intensive group 110-130mmHg
- Standard group 130-150mmHg
- Median FU: 3.3 years

# Office BP Measurements




## No. with Data

Standard treatment	4268	4139	4086	4092	4072	3954	3857	1885
Intensive treatment	4243	4128	4086	4049	4050	3969	3894	1850

## Mean No. of Medications

Standard treatment	1.4	1.5	1.5	1.5	1.5	1.5	1.5	1.5
Intensive treatment	1.5	1.7	1.8	1.8	1.9	1.9	1.9	1.9

# Cumulative Incidence of the Primary Outcome



## No. at Risk

Standard treatment	4268	4147	4070	4000	3938	3849	3664	1200
Intensive treatment	4243	4174	4109	4039	3970	3867	3694	1234

# BP CLASSIFICATION

## (2003 JNC 7 and 2017 ACC/AHA Guidelines)

SBP		DBP	2003 JNC7	2017 ACC/AHA
<120	and	<80	Normal BP	Normal BP
120-129	and	<80	Prehypertension	Elevated BP
130-139	or	80-89		Stage 1 hypertension
140-159	or	90-99	Stage 1 hypertension	Stage 2 hypertension
≥160	or	≥100	Stage 2 hypertension	Stage 2 hypertension

Area of difference

- Blood Pressure should be based on an average of  $\geq 2$  careful readings on  $\geq 2$  occasions
- Adults with SBP or DBP in two categories should be designated to the higher BP category

# 2017 ACC/AHA BP Guideline: Thresholds for Drug Treatment

SBP	DBP	CVD Risk/other circumstances	Recommended Treatment
<120 and <80 (Normal)		N/A	Healthy Lifestyle
120-129 and <80 (Elevated)		N/A	Nonpharmacological therapy
130-139 or 80-89 (Stage 1 Hypertension)		- No CVD - 10-yr ASCVD risk <10%*	Nonpharmacological therapy
		- CVD, or - 10-year ASCVD risk ≥ 10%	Nonpharmacological therapy and Antihypertensive drug therapy
		Diabetes or CKD	
130-139 (Stage 1 Hypertension)		Age ≥ 65 years	Antihypertensive drug therapy
≥140 or ≥90 (Stage 2 Hypertension)		N/A	

\* AHA/ACC 2013 Pooled Cohort CVD Risk Equations

## COMPARISON OF CVD EVENTS AND DEATH PREVENTED WITH ADHERENCE TO 2 GUIDELINE RECOMMENDATIONS

- 1) Estimation of proportion of US adults in BP categories using NHANES
- 2) Incidence of major CVD events & all-cause mortality by modeling 4 large community-based cohort studies (ARCS, CV Health, Framingham, and MESA)
- 3) Network meta-analysis (42 RCTs) to estimate HRs for outcomes and determine population-attributable risks and events reduced.



Characteristic	2014 Evidence-Based Guideline	2017 ACC/AHA Guideline
BP threshold for initiation of antihypertensive drugs	$\geq 140/90$ (<age 60) $\geq 150/90$ ( $\geq$ age 60)	$\geq 140/90$ (gen. population) $\geq 130/80$ (high CVD risk)
BP goal of treatment	$< 140/90$ (<age 60) $< 150/90$ ( $\geq$ age 60)	$< 130/80$
Annual CVD event reduction ( $\geq$ age 40)	270,000	610,000 (NNT=70)
Annual reduction in death ( $\geq$ age 40)	177,000	334,000 (NNT=129)

# ASSOCIATION OF NON-HYPERTENSIVE LEVELS OF SBP & CVD

## *In the Absence of Traditional CVD Risk Factors*

MESA FU of 14.5 years in 1457 adults, mean age 58 y and free of ASCVD with SBP 90–129 mm Hg, LDL-C <160 mg/dL, HDL-C 40+ mg/dL, no DM, no tobacco use, no treatment for hyperlipidemia or DM

Higher levels of SBP @ baseline associated with development of CVD Risk Factors



Adjusted for age, sex, race/ethnicity, diastolic blood pressure, total cholesterol level, high-density lipoprotein cholesterol level, fasting blood glucose level, body mass index, income, educational level, ever smoking, and prediabetes.

### Hazard of Cardiovascular Disease by Systolic Blood Pressure Group

Table 2. Hazard of Cardiovascular Disease by Systolic Blood Pressure Group

Characteristic	Systolic blood pressure, mm Hg				P value for trend
	90-99	100-109	110-119	120-129	
Unadjusted	1 [Reference]	3.04 (1.05-8.80)	3.49 (1.23-9.90)	6.31 (2.24-17.73)	<.001
Model 1 <sup>a</sup>	1 [Reference]	2.70 (0.93-7.85)	2.64 (0.93-7.82)	3.76 (1.33-10.69)	.07
Model 2 <sup>b</sup>	1 [Reference]	3.00 (1.01-8.88)	3.10 (1.03-9.28)	4.58 (1.47-14.27)	.06

<sup>a</sup> Adjusted for age, sex, race/ethnicity.

<sup>b</sup> Model 1 adjustments plus diastolic blood pressure, total cholesterol level, high-density lipoprotein cholesterol level, fasting blood glucose level, body mass index, income, educational level, ever smoking, and prediabetes.

Whelton S  
*et al. JAMA Cardiol.*  
2020;5:1011-1018.

# ESH 2023

TABLE 1 - Classification of office BP and definitions of hypertension grades

Category	Systolic (mmHg)		Diastolic (mmHg)
Optimal	<120	and	<80
Normal	120–129	and	80–84
High-normal	130–139	and/or	85–89
Grade 1 hypertension	140–159	and/or	90–99
Grade 2 hypertension	160–179	and/or	100–109
Grade 3 hypertension	≥180	and/or	≥110
Isolated systolic hypertension <sup>a</sup>	≥140	and	<90
Isolated diastolic hypertension <sup>a</sup>	<140	and	≥90

Hypertension disease staging	Other risk factors, HMOD, CVD or CKD	BP (mmHg) grading			
		High-normal SBP 130–139 DBP 85–89	Grade 1 SBP 140–159 DBP 90–99	Grade 2 SBP 160–179 DBP 100–109	Grade 3 SBP ≥ 180 DBP ≥ 110
Stage 1	No other risk factors <sup>a</sup>	Low risk	Low risk	Moderate risk	High risk
	1 or 2 risk factors	Low risk	Moderate risk	Moderate to high risk	High risk
	≥3 risk factors	Low to moderate risk	Moderate to high risk	High risk	High risk
Stage 2	HMOD, CKD grade 3, or diabetes mellitus	Moderate to high risk	High risk	High risk	Very high risk
Stage 3	Established CVD or CKD grade ≥4	Very high risk	Very high risk	Very high risk	Very high risk

	<50 years	60–69 years	≥70 years	
	<2.5%	<5%	<7.5%	Complementary risk estimation in Stage 1 with SCORE2/SCOR2-OP
	2.5 to <7.5%	5 to <10%	7.5 to <15%	
	≥7.5%	≥10%	≥15%	

Cardiovascular risk according to grade and stage of hypertension.

### 3.6 Target blood pressure

#### 6. RECOMMENDATION ON TARGET BLOOD PRESSURES

WHO recommends a target blood pressure treatment goal of <140/90 mmHg in all patients with hypertension without comorbidities.


*Strong recommendation, moderate-certainty evidence*

WHO recommends a target systolic blood pressure treatment goal of <130 mmHg in patients with hypertension and known cardiovascular disease (CVD).

*Strong recommendation, moderate-certainty evidence*

WHO suggests a target systolic blood pressure treatment goal of <130 mmHg in high-risk patients with hypertension (those with high CVD risk, diabetes mellitus, chronic kidney disease).

*Conditional recommendation, moderate-certainty evidence*



NOTE: Monitor potassium and kidney function when starting or changing the dose of ACEi/ARB or thiazide/thiazide-like diuretic, if testing is readily available and does not delay treatment.

This protocol is contraindicated for women who are or could become pregnant. Neither an ACEi or ARB should be given to pregnant women.

### Prescribing patterns:

- Start with dual combination therapy in most patients
- Uptitrate to maximum well tolerated doses and to triple therapy if needed
- **Once daily (preferred in the morning)**
- **Add further drugs if needed**
- **Preferred use of SPCs at any step**



T/TL **Diuretic<sup>a</sup>**


### Additional drug classes

#### General antihypertensive therapy:

- Steroidal MRA
- Loop Diuretic
- Alpha-1 Blocker
- Centrally acting agent
- Vasodilator

#### Special comorbidities:

- ARNi
- SGLT2i
- Non-Steroidal MRA









Marriott / Barcroft USA

## Yanomami People



# Not All Hyperaldosteronism is the Same




## Brazilian Pit Viper

*(Bothrops jararaca)*



[www.faunaparaguay.com](http://www.faunaparaguay.com)

*“Over thousands of years, the same environmental pressures that forced Yanomamo and other terrestrial animals to evolve a hyperactive RAAS, also led Bothrops jararaca to conserve an efficient killing mechanism that targeted its enemies’ haemodynamic vulnerabilities. The bradykinin-potentiating peptides that would become the first ACEi’s were, in essence, the viper’s weapon of choice in a predator-prey arms race.”*




## High prevalence and a long delay in the diagnosis of primary aldosteronism among patients with young-onset hypertension

Sarah Alam<sup>1</sup> | Devasenathipathy Kandasamy<sup>2</sup> | Alpesh Goyal<sup>1</sup> |  
Sreenivas Vishnubhatla<sup>3</sup> | Sandeep Singh<sup>4</sup> | Ganesan Karthikeyan<sup>4</sup> |  
Rajesh Khadgawat<sup>1</sup> 



“PA: we are not addressing even the tip  
of the iceberg.”

# Variable Aldosterone Production



# The Prevalence of Primary Aldosteronism

*There is no reference/gold-standard diagnostic*

**ARR**



**Arbitrary Thresholds**  
**30, 25, 20, etc.**

**Aldosterone**



**Arbitrary Thresholds**  
**20, 15, 10 ng/dL, etc.**


**Confirmatory Aldosterone  
Suppression Tests**




**Multiple Protocols**  
**Arbitrary Thresholds**

# The Prevalence of Primary Aldosteronism

24h Urinary Aldosterone Excretion (mcg)




# Prevalence of Overt Primary Aldosteronism




# The Prevalence of Primary Aldosteronism

## Best 4<sup>th</sup> Drug: MR Antagonist (& ENaCi)



# Severity Spectrum of Primary Aldosteronism



## How to Screen for PA?

**We do a poor job of screening for primary aldosteronism**

Less than **3%** of patients with resistant hypertension and hypokalemia in major academic medical centers were ever screened for PA

Ruhle et al. *Surgery* 2019  
Jaffe et al. *Hypertension* 2020

# How to Screen for PA?

## Philosophy #1: "The Purist"

*Eliminate all potential confounders of renin and aldosterone*


- Withdraw all potential confounding medications for 2-6 weeks
  - MRA's ENaCi's
  - ACEi, ARBs, BB's
- Serum K<sup>+</sup> ~4.0
  - supplementation after med withdrawal
- Morning labs only
- Estrogen/menstrual cycle

## Philosophy #2: "Pragmatic"



***"Don't Hesitate, Re-Calibrate!"***

- Measure at any time on any medication
  - If renin is suppressed, results are interpretable
- Positive: **"renin-independent aldosteronism"**
  - Suppressed renin  
( $<0.60-1.0$  ng/mL/h or  $<5-10$  mU/L)
  - Inappropriate aldosterone ( $>15, >10, >5$  ng/dL)
- Negative or Uninterpretable/Confounded:
  - Unsuppressed renin
  - Insufficiently high aldosterone

# Longitudinal Cohort Study



## Aldosterone, but NOT Ang II ...



### Innate Immunity

Ang II

-

Aldo

+++

---

---

**MALIGNANT HYPERTENSION  
PRODUCED BY TREATMENT WITH  
DESOXYCORTICOSTERONE ACETATE  
AND SODIUM CHLORIDE\***

By Hans Selye, M.D., Ph.D., D.Sc., F.R.S.C.,  
C. E. Hall,† M.Sc. and E. M. Rowley, B.Sc.


*Montreal*

THE first observations concerning the production by desoxycorticosterone acetate (D.C.A.) of nephrosclerosis were based upon experiments on chicks.<sup>1</sup> Young birds are particularly sensitive test objects for the demonstration of this hormone action. Indeed, subsequent experimentation showed that most other laboratory animals develop little or no nephrosclerosis if their diet contains normal or low concentrations of NaCl. However, combined treatment with D.C.A. and NaCl results in the production of particularly marked and malignant nephrosclerosis not only in the chick,<sup>2</sup> but also in the dog, rat and monkey.<sup>3</sup>


In the spontaneously occurring nephrosclerosis of man, a rise in blood pressure and morphological changes in extra-renal blood vessels—especially those of the pancreas—are very characteristic. It was therefore decided to take advantage of the particular effectiveness of combined treatment with D.C.A. and NaCl in order

\* From the Department of Anatomy, McGill University, Montreal.


† Work performed during the tenure of a National Research Council Studentship.




# RAS-Fingerprint




baseline




30min



60min



90min



58 Jahre männlich

- Krea 2,3 mg/dl, CKD G3b A1
- NIDDM, HbA1c 5.4%
- St.p. Insult 2019
- Meds: Trajenta 5 mg/d, Amlodipin 10 mg/d, Ramipril 10 mg/d, TASS 100 mg/d
- RR 145/85 mmHg – Renin-Aldo: normal

Geb. Dat.: 21.02.1964 (M)

Untersuchung	Ergebnis	Einheit	Referenzbereich
--------------	----------	---------	-----------------

**SONSTIGE**

\* RAAS Triple A Test  
(Hypertoniediagnostik)

Angiotensin I	141.9	pmol/L
Angiotensin II	<4.8	pmol/L
Aldosteron MS	248.1	pmol/L
PRA-S (Renin Aktivität Angiotensin-basiert)	146.7	pmol/L

ACE-S (ACE Aktivität Angiotensin-basiert)	<0.03	pmol/L / pmol/L
--	-------	-----------------


AA2-R (Aldosteron/Angiotensin 2 Ratio)	>51.70	pmol/L / pmol/L
---	--------	-----------------

RAAS Triple A Interpretation


Effiziente ACE Hemmung  
Renovaskuläre Hypertension negativ  
Primärer Hyperaldosteronismus (PHA) positiv  
=> Mineralokortikoidrezeptor Antagonist und Kalium-Kontrolle  
=> Weitere PHA Abklärung empfohlen (Leitlinien)



**Prescription: ACE-Inhibitor**

**Blood Pressure Hormone Levels (LC-MS/MS)**



**RAAS Triple-A™ Evaluation**





- 45 Jahre männlich
  - HTN I, Hyperchol., BMI 25
  - Amlodipin 5 mg/Tag
- 
- ✓ Urlaub: RR > 220/100 mmHg, Cephalea
  - ✓ Work-Up: CCT, Nieren-US, MRT Abdomen
  - ✓ 4 x antihypertensive Therapie (145-185 mmHg syst),
  - ✓ Krea 1,6 mg/dl

Triple A Test: Ang-II und PRA-S exzessiv erhöht



FD-Nieren:

NAST rechts > links bei familiärer Hypercholesterinämie  
Nierenarteriestent bds.: Krea 1.1 mg/dl, RR normal

- 58 Jahre weiblich, BMI 23
- St.p. Pankreas-Nieren-Tx 2008
- Krea 0.8 mg/dl, HbA1c 5.4%
- Meds: Tacrolimus, MM
- RR 120/70 mmHg

05/2022 RR 170/90 mmHg

Amlodipin 10 mg/d plus Doxazosin 8 mg/d

Laborwerte o.B.


Renin-Aldo: normal

Triple A Test: Aldo, Ang-II und PRA-S exzessiv erhöht


Candesartan 8 mg  
RR 125/75 mmHg


FD-Nieren:  
Tx-Niere o.B.  
Eigennieren NAST links

## Blood Pressure Hormone Levels (LC-MS/MS)



## RAAS Triple-A™ Evaluation





# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JANUARY 2, 2014

VOL. 370 NO. 1

## Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis



Christopher J. Cooper, M.D., Timothy P. Murphy, M.D., Donald E. Cutlip, M.D., Kenneth Jamerson, M.D., William Henrich, M.D., Diane M. Reid, M.D., David J. Cohen, M.D., Alan H. Matsumoto, M.D., Michael Steffes, M.D., Michael R. Jaff, D.O., Martin R. Prince, M.D., Ph.D., Eldrin F. Lewis, M.D., Katherine R. Tuttle, M.D., Joseph I. Shapiro, M.D., M.P.H., John H. Rundback, M.D., Joseph M. Massaro, Ph.D., Ralph B. D'Agostino, Sr., Ph.D., and Lance D. Dworkin, M.D., for the CORAL Investigators\*

### EDITORIAL

**M. A. C. ONUIGBO, MD, MSc, FWACP, FASN, MBA**

College of Medicine, Mayo Clinic, Rochester, MN;  
Department of Nephrology, Mayo Clinic Health System, Eau Claire, WI

# Stenting may benefit select patients with severe renal artery stenosis





*Everything you can imagine is real...*



### R1: BP threshold for starting drug treatment

Those with diagnosis of HTN and BP of  $\geq 140/\geq 90$  mmHg

Those with CVD and SBP  $\geq 130$ – $139$  mmHg

*Recommendation: strong*

*Evidence: moderate–high certainty*

Those without CVD but with high CVD risk, diabetes, CKD and

SBP  $\geq 130$ – $139$  mmHg

*Recommendation: conditional*

*Evidence: moderate–high certainty*



### R2 & 3: Whether screening and assessment are needed before treatment is started

Obtain tests to screen for comorbidities and conduct CV risk assessment

**but only if it doesn't delay treatment**

*Recommendation: conditional*

*Evidence: low certainty*



### R4: Which drug(s) to prescribe

Any of these drug classes:

**diuretics/ACEi, ARB/CCBs**

*Recommendation: strong*

*Evidence: high certainty*

### R5: Combination therapy

To improve adherence and persistence **combination therapy recommended** preferably in a **single pill**

*Recommendation: conditional*

*Evidence: moderate certainty*

## Targets and follow-up



### R6: BP target for control of HTN

**140/90** mmHg

in those without comorbidities

SBP **130** mmHg

in those with CVD

*Recommendation: strong*

*Evidence: moderate certainty*

SBP **<130** mmHg

in those with high CVD risk, diabetes and CKD

*Recommendation: conditional*

*Evidence: moderate certainty*



### R7: Follow-up intervals

**Monthly follow up**

until patient reaches target BP

*Recommendation: conditional*

*Evidence: low certainty*

**3–6 month follow up**

once target BP is reached

*Recommendation: conditional*

*Evidence: low certainty*



### R8: Use of nonphysician HCWs in further management of HTN

Treatment can be provided by

**nonphysician professionals**

as long as they are given training, prescribing authority, management protocols and physician oversight

*Recommendation: conditional*

*Evidence: low certainty*

- 58 Jahre weiblich, BMI 23
- St.p. Pankreas-Nieren-Tx 2008
- Krea 0.8 mg/dl, HbA1c 5.4%
- Meds: Tacrolimus, MM
- RR 120/70 mmHg

05/2022 RR 170/90 mmHg

Amlodipin 10 mg/d plus Doxazosin 8 mg/d

Laborwerte o.B.


Renin-Aldo: normal

Triple A Test: Aldo, Ang-II und PRA-S exzessiv erhöht

Candesartan 8 mg  
RR 125/75 mmHg

FD-Nieren:  
Tx-Niere o.B.  
Eigennieren NAST links

### Blood Pressure Hormone Levels (LC-MS/MS)



### RAAS Triple-A™ Evaluation

